Ionis Pharmaceuticals (IONS) Tops Q4 EPS by $1.13

Ionis Pharmaceuticals (NASDAQ: IONS) reported Q4 EPS of $1.41, $1.13 better than the analyst estimate of $0.28. Revenue for the quarter came in at $440 million versus the consensus estimate of $259.15 million.

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Nike names former Pfizer CFO David Denton as new finance chief